A Single-Center, Open-label, 2-period, non-fasting study to evaluate the effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Female Volunteers
Latest Information Update: 27 Mar 2019
At a glance
- Drugs Venetoclax (Primary) ; Azithromycin
- Indications Acute myeloid leukaemia; Breast cancer; Cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Pharmacokinetics
- 19 Mar 2019 Status changed from completed to suspended according to an Abbvie media release.
- 19 Mar 2019 According to an AbbVie media release, the company announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials evaluating venetoclax for the investigational treatment of multiple myeloma. The partial clinical hold follows a review of data from BELLINI study.As a result of this action, no new patients should be enrolled in any studies of venetoclax for multiple myeloma until a further analysis of the data is completed
- 08 Oct 2018 New trial record